Regarding the last part of your post, I don’t think it
Regarding the last part of your post, I don’t think it was Dr Jay’s communications at all that resulted in “The Letter”: The previous blunders, amateur approaches and incomplete/mis-formatted BLA filings as well as blatantly ignoring the FDA warnings contributed. The bogus press releases and Proactive videos made anyone with knowledge of the rules that are expected in PhRMA/Biotech and regulatory affairs, cringe as they were so out of line with what can legally (jmo - not legal advice) be said from a company either developing a drug or one that has already been approved.
It is a very serious offense to misrepresent a drug before it has passed certain hurdles established by the FDA. That is not a slight whatsoever on the efficacy of LL and what we all were witnessing across multiple disease states. You just can’t use words like (these are my words)- Amazing, Better, Beautiful…; this is a standard (and bare minimum) understanding in the Industry and NP didn’t get that. The Amerex debacle made things terrible for LL to get approved.
Then there was a pitchforks and torches period where mob mentality ruled and cydy enthusiasts were pressing to write the FDA and demand approval, without LL having passed the proper regulatory hurdles. The FDA took this to mean thar NP ‘s premature and out of bounds languaging was getting through to the “Lay” (their word from the letter) and they have to take that seriously because it, again, Hadn’t gone through the proper regulatory process and cross the proper hurdles to obtain approval.
What is the letter harsh? Absolutely. Could it have been handled a different way? Absolutely. I disagree with many of the characterizations of LL in that letter, but the letter was not caused by Dr. Jay. It was years in the making from the fumblers of Amerex Along with the points that I have noted above.
*I again implore folks to let SA handle things.
Having said that I am 100% confident that Dr. Jay is the right man for the job and I say this because of the way he speaks. Like it or not, he has to be respectful of the FDA and he has to speak and write in a language that Does not trigger them. They are bureaucrats and they work under a system. That system has certain steps that must occur and If you step out of line, they will push back. Dr. Jay understands this and his experience in clinical trials and regulatory affairs of drug approvals are a godsend to our cause. His passion for improving, the lives of patience is a bonus to say the least.
20
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...
Continue Reading
Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...
Continue Reading
Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
Top 5 Most Recently Viewed Articles
Uber's Position in Autonomous Driving Technology Gary Black, Managing Director of The Future Fund LLC, shares insights on Uber Technologies Inc. (NYSE: UBER) and the evolving landscape of autonomous driving technology. He believes that as automated driving continues to advance, Uber stands to benefit more than any other ride-hailing company in the market. Understanding...
Continue Reading
Gilat Satellite Networks Captures Significant Orders for Connectivity Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a leader in satellite networking technology, has made news by securing more than $18 million in new orders specifically for its in-flight connectivity (IFC) solutions. This impressive achievement underscores the increasing demand for quality...
Continue Reading
A Wine Festival Tradition in Eastern China A captivating wine-themed cultural festival took place in Mengshan Town, Shanggao County, aiming to uplift the local wine industry. This annual event draws visitors from various regions, uniting them in a shared love for fine wines and cultural experiences. The air was filled with excitement as participants engaged in thrilling...
Continue Reading
Understanding Recent Transactions at Danske Bank A/S Danske Bank A/S has been actively engaging in its share buy-back program, as evident from its latest managerial transactions. This initiative allows shareholders greater confidence and highlights the bank's proactive approach in strengthening its share value. Significance of Managerial Transactions Transactions carried...
Continue Reading
Opus Technologies Forms Strategic Alliance for Payment Solutions Opus Technologies has just unveiled a major strategic partnership with a leading company in payment solutions. This collaboration is focused on enhancing payment network compliance solutions for clients who navigate an increasingly regulated landscape. The Power of Synergy This alliance between Opus...
Continue Reading